| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Nandini Dey | |
| Pradip De | |||
| Brett Rozeboom | |||
| Jordyn Kreutzfeldt | |||
| P2860 | cites work | Breast cancer intrinsic subtype classification, clinical use and future trends | Q26773761 |
| Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer | Q27003258 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial | Q27851705 | ||
| Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Q27853337 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 | ||
| Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene | Q28286890 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial | Q33441996 | ||
| Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions | Q33816106 | ||
| Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab | Q33912075 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. | Q34484185 | ||
| Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. | Q34578377 | ||
| A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer | Q34650878 | ||
| Resistance to trastuzumab: a necessary evil or a temporary challenge? | Q34993786 | ||
| HER2 therapy: molecular mechanisms of trastuzumab resistance. | Q35633712 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. | Q35842144 | ||
| Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer | Q35992905 | ||
| Trastuzumab: updated mechanisms of action and resistance in breast cancer | Q36036437 | ||
| Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence | Q36250585 | ||
| Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer | Q36472437 | ||
| Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance | Q36860992 | ||
| Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes | Q36891705 | ||
| Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US | Q37390917 | ||
| The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine | Q37433324 | ||
| Alternative intracellular routing of ErbB receptors may determine signaling potency | Q38337018 | ||
| Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer | Q38743961 | ||
| Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. | Q39068453 | ||
| Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study | Q39605778 | ||
| T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab | Q39685521 | ||
| Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease | Q40630247 | ||
| Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. | Q41655720 | ||
| Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model | Q41676872 | ||
| Review of recent trials of chemotherapy for advanced breast cancer: the taxanes | Q41704937 | ||
| Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients | Q42871099 | ||
| Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall | Q43180234 | ||
| 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. | Q43784378 | ||
| Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results | Q44722190 | ||
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial | Q45073151 | ||
| Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer | Q45287928 | ||
| Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial | Q46419524 | ||
| Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment | Q46641346 | ||
| Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial | Q46839548 | ||
| Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? | Q47813921 | ||
| 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial | Q47973074 | ||
| 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. | Q48055457 | ||
| Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review | Q48162978 | ||
| First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. | Q51170722 | ||
| The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen | Q52827123 | ||
| Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. | Q53394493 | ||
| Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). | Q53521179 | ||
| Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. | Q53554133 | ||
| Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). | Q53985281 | ||
| HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma | Q54272953 | ||
| Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? | Q54509553 | ||
| Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. | Q54978057 | ||
| Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC). | Q55006124 | ||
| De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± wee | Q56968853 | ||
| Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2+ breast cancers: Implications to the ExteNET trial | Q57053749 | ||
| Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer | Q57105786 | ||
| Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial | Q57391359 | ||
| Pyrotinib: First Global Approval | Q57809885 | ||
| Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer | Q62022868 | ||
| Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study | Q64109775 | ||
| Neoadjuvant treatment of HER2-positive breast cancer: should therapy differ based on hormone receptor status? | Q64325820 | ||
| Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer | Q71059676 | ||
| c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases | Q71692738 | ||
| c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer | Q72673347 | ||
| erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer | Q77331953 | ||
| Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial | Q87702640 | ||
| Neratinib: Inching Up on the Cure Rate of HER2+ Breast Cancer? | Q88866697 | ||
| Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial | Q88933702 | ||
| De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry | Q89646953 | ||
| Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic | Q89648608 | ||
| Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies | Q90371029 | ||
| First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase | Q90938965 | ||
| Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial | Q91592820 | ||
| Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis | Q91738536 | ||
| Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer | Q91873787 | ||
| Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer | Q91875831 | ||
| Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials | Q92269774 | ||
| Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women | Q92337356 | ||
| 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial | Q92614334 | ||
| Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study | Q92726455 | ||
| Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10 | Q92814902 | ||
| P433 | issue | 4 | |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 1045-1067 | |
| P577 | publication date | 2020-04-01 | |
| P1433 | published in | American Journal of Cancer Research | Q17511667 |
| P1476 | title | The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies | |
| P478 | volume | 10 |
Search more.